Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Drug Discovery

Vertex taps Mammoth Bio for CRISPR work

by Ryan Cross
October 30, 2021 | A version of this story appeared in Volume 99, Issue 40

Vertex Pharmaceuticals is expanding its investment in CRISPR through a partnership with Mammoth Biosciences, a start-up cofounded by CRISPR gene-editing inventor Jennifer Doudna. Vertex will pay Mammoth $41 million up front and up to $650 million in future payments to use the start-up’s ultracompact Cas enzymes, whose small size could make delivery into the body easier. The firms will develop therapies for two undisclosed genetic diseases. Vertex is already developing a gene-editing therapy for sickle cell disease with the firm CRISPR Therapeutics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.